Table 2.
Pharmacokinetic parameters of daclizumab after administration of daclizumab 150 mg subcutaneously every 4 weeks in patients with RMS50
| Parameter | Dose 1 (week 0) | Dose 6 (week 20) |
|---|---|---|
| Median (range) Tmax, day | 7.00 (3.00–30.0) | 5.03 (2.97–14.2) |
| Cmax, μg/mL | ||
| Mean (SD) | 12.6 (4.64) | 29.1 (10.8) |
| Median (min–max) | 12.3 (6.46–23.8) | 24.9 (13.2–53.5) |
| Cmin, μg/mL | ||
| Mean (SD) | — | 14.9 (6.33) |
| Median (min–max) | — | 13.8 (6.84–32.3) |
| AUCtau, d· μg/mL | ||
| Mean (SD) | 255 (88.6) | 638 (256) |
| Median (min–max) | 246 (143–497) | 549 (305–1,286) |
| CL/F, L/d | ||
| Mean (SD) | — | 0.274 (0.108) |
| Median (min–max) | — | 0.273 (0.117–0.491) |
| t1/2, d | ||
| Mean (SD) | — | 21.9 (5.47) |
| Median (min–max) | — | 21.1 (13.5–34.3) |
| Rac | ||
| Mean (SD) | — | 2.55 (0.578) |
| Median (min–max) | — | 2.71 (1.34–3.54) |
Notes: Reprinted from Tran et al,50 copyright (2016), with permission from Dove Medical Press Ltd.
Abbreviations: RMS, relapsing multiple sclerosis; Tmax, time to maximum observed concentration; Cmax, maximum observed concentration; SD, standard deviation; min, minimum; max, maximum; Cmin, minimum observed concentration; AUCtau, area under the concentration–time curve within a dosing interval; CL/F, apparent clearance; L, liter; t1/2, elimination half-life; Rac, accumulation ratio.